Paxlovid Cuts Covid Deaths Among Older People, Israeli Study Finds

September 1, 2022

(New York Times) – Paxlovid, the Covid-19 treatment made by Pfizer, reduced hospitalizations and deaths in older patients during the Omicron surge in Israel earlier this year, but made no difference for patients under 65 at high risk for severe disease, new research has found. The study is one of the first published examinations of the real-life effectiveness of Paxlovid against the Omicron variant, now the dominant version of the coronavirus. Pfizer’s trials of Paxlovid were conducted during a surge of the Delta variant last year, and included only unvaccinated individuals. (Read More)